SNX-111 data

Results of a Phase I/II dose-escalating study of the SNX-111 analgesic demonstrated that the compound has the potential to provide relief in patients who have failed all other pain therapy including intrathecal opiates, according to data presented at the American Pain Society meeting in Los Angeles.

The compound was administered in doses ranging from 0.3-10 ng/kg/hr to 7 patients who had either severe pain due to cancer, or nonmalignant neuropathic pain. Six responded symptomatically in the dose escalation phase and 4 entered long-term treatment, remaining virtually symptom-free with maintenance of the drug of up to 8 months. ...